{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T06:22:30Z","timestamp":1777530150860,"version":"3.51.4"},"reference-count":68,"publisher":"SAGE Publications","issue":"6","license":[{"start":{"date-parts":[[2014,4,25]],"date-time":"2014-04-25T00:00:00Z","timestamp":1398384000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Cardiovasc Pharmacol Ther"],"published-print":{"date-parts":[[2014,11]]},"abstract":"<jats:p>With the release of the 2013 American College of Cardiology\/American Heart Association (ACC\/AHA) Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults, emphasis has been placed on using evidence-based intensity of therapy to reduce atherosclerotic cardiovascular disease (ASCVD) risk, rather than focusing on goal cholesterol levels. Before initiating therapy, however, it is critical that physicians and patients discuss 4 key topics: (1) the benefit of ASCVD risk reduction, (2) medication adverse effects, (3) drug\u2013drug interactions, and (4) patient preferences. To facilitate discussion of statin adverse effects, we present here an evidence-based review of the 5 Ms of statin adverse effects: metabolism, muscle, medication interactions, major organ effects, and memory. \u201cMetabolism\u201d represents the small risk of new-onset diabetes that comes with statins, which is highest in those with diabetes risk factors. \u201cMuscle\u201d requires discussion of the wide range of muscle symptoms that occur with statins but emphasizes that these have been no more prevalent than those experienced with placebo in randomized controlled trials (RCTs). \u201cMedication interactions\u201d emphasize that statins interact with numerous medications. Interaction profiles vary widely between statins, and patients should be made aware of the most common interactions with their prescription. \u201cMajor organ effects\u201d prompt the physician to review the possibility of a transient transaminitis as well as the recent observation of rare acute kidney injury with statin use. Both are rare and do not require routine monitoring. Finally, \u201cmemory\u201d references the recent observational data suggesting statins may contribute to memory loss and confusion, both of which have not been observed in RCTs and resolve with drug cessation. Reviewing these common effects has the possibility to strengthen the doctor\u2013patient relationship and boost both medication adherence and patient satisfaction.<\/jats:p>","DOI":"10.1177\/1074248414529622","type":"journal-article","created":{"date-parts":[[2014,4,25]],"date-time":"2014-04-25T23:32:47Z","timestamp":1398468767000},"page":"533-542","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":23,"title":["Addressing Statin Adverse Effects in the Clinic"],"prefix":"10.1177","volume":"19","author":[{"given":"Daniel H.","family":"Katz","sequence":"first","affiliation":[{"name":"Department of Medicine, Division of Cardiology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sunny S.","family":"Intwala","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Cardiology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neil J.","family":"Stone","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Cardiology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2014,4,25]]},"reference":[{"key":"bibr1-1074248414529622","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1L181"},{"key":"bibr2-1074248414529622","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)61350-5"},{"key":"bibr3-1074248414529622","author":"Stone N","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"bibr4-1074248414529622","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.20.4.614"},{"key":"bibr5-1074248414529622","doi-asserted-by":"publisher","DOI":"10.1007\/s10557-005-5202-5"},{"key":"bibr6-1074248414529622","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(03)13636-7"},{"key":"bibr7-1074248414529622","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0807646"},{"key":"bibr8-1074248414529622","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.103.3.357"},{"key":"bibr9-1074248414529622","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)61965-6"},{"key":"bibr10-1074248414529622","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2011.860"},{"key":"bibr11-1074248414529622","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCOUTCOMES.111.000071"},{"key":"bibr12-1074248414529622","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)61190-8"},{"key":"bibr13-1074248414529622","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2012.09.042"},{"key":"bibr14-1074248414529622","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.98.23.2513"},{"key":"bibr15-1074248414529622","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.26.10.2713"},{"key":"bibr16-1074248414529622","doi-asserted-by":"publisher","DOI":"10.1172\/JCI110530"},{"key":"bibr17-1074248414529622","doi-asserted-by":"publisher","DOI":"10.1016\/0021-9150(82)90070-3"},{"key":"bibr18-1074248414529622","doi-asserted-by":"publisher","DOI":"10.1016\/j.cjca.2011.05.007"},{"key":"bibr19-1074248414529622","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-150-12-200906160-00009"},{"key":"bibr20-1074248414529622","doi-asserted-by":"publisher","DOI":"10.1001\/jama.289.13.1681"},{"key":"bibr21-1074248414529622","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacl.2012.03.003"},{"key":"bibr22-1074248414529622","doi-asserted-by":"publisher","DOI":"10.1016\/j.trsl.2008.11.002"},{"key":"bibr23-1074248414529622","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.2011.04321.x"},{"key":"bibr24-1074248414529622","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2007.02.049"},{"key":"bibr25-1074248414529622","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2012.04.026"},{"key":"bibr26-1074248414529622","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.112.136101"},{"key":"bibr27-1074248414529622","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1988.03410020105038"},{"key":"bibr28-1074248414529622","volume-title":"Product information. Zocor\u00ae (simvastatin)"},{"key":"bibr29-1074248414529622","volume-title":"Product information. Mevacor\u00ae (lovastatin)"},{"key":"bibr30-1074248414529622","volume-title":"Product information. Lipitor\u00ae (atorvastatin calcium)"},{"key":"bibr31-1074248414529622","volume-title":"Product information. Lescol\u00ae (fluvastatin sodium)"},{"key":"bibr32-1074248414529622","volume-title":"Product information. Pravachol\u00ae (pravastatin sodium)"},{"key":"bibr33-1074248414529622","volume-title":"Product information. Crestor\u00ae (rosuvastatin calcium)"},{"key":"bibr34-1074248414529622","volume-title":"Product information. Livalo\u00ae (pitavastatin)"},{"key":"bibr35-1074248414529622","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2012.02.022"},{"key":"bibr36-1074248414529622","doi-asserted-by":"publisher","DOI":"10.1016\/j.clpt.2006.09.003"},{"key":"bibr37-1074248414529622","doi-asserted-by":"publisher","DOI":"10.2174\/157016208786501481"},{"key":"bibr38-1074248414529622","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2006.03.003"},{"key":"bibr39-1074248414529622","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-158-12-201306180-00004"},{"key":"bibr40-1074248414529622","doi-asserted-by":"publisher","DOI":"10.1592\/phco.23.15.1663.31953"},{"key":"bibr41-1074248414529622","doi-asserted-by":"publisher","DOI":"10.1592\/phco.21.7.767.34577"},{"key":"bibr42-1074248414529622","doi-asserted-by":"publisher","DOI":"10.1592\/phco.23.6.726.32184"},{"key":"bibr43-1074248414529622","doi-asserted-by":"publisher","DOI":"10.1592\/phco.29.7.800"},{"key":"bibr44-1074248414529622","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)09327-3"},{"key":"bibr45-1074248414529622","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)11600-X"},{"key":"bibr46-1074248414529622","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2012.07.007"},{"key":"bibr47-1074248414529622","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000182897.18229.ec"},{"key":"bibr48-1074248414529622","unstructured":"FDA Drug Safety Communication: Important safety label changes to cholesterol-lowering statin drugs. http:\/\/www.fda.gov\/drugs\/drugsafety\/ucm293101.htm. Accessed July 15, 2013."},{"key":"bibr49-1074248414529622","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-159-10-201311190-00007"},{"key":"bibr50-1074248414529622","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2013.07.013"},{"key":"bibr51-1074248414529622","unstructured":"Roberts MD. CRESTOR (Rosuvastatin calcium) NDA 21-366 JUPITER. United States Food and Drug Administration Endocrinologic and Metabolic Drugs Advisory Committee. 2009; www.fda.gov\/downloads\/advisorycommittees\/committeesmeetingmaterials\/drugs\/endocrinologicandmetabolicdrugsadvisorycommittee\/ucm194918.pdf. Accessed July 15, 2013."},{"key":"bibr52-1074248414529622","doi-asserted-by":"publisher","DOI":"10.4065\/mcp.2009.0365"},{"key":"bibr53-1074248414529622","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosissup.2004.08.027"},{"key":"bibr54-1074248414529622","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000017634.00171.24"},{"key":"bibr55-1074248414529622","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2005.12.010"},{"key":"bibr56-1074248414529622","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2005.02.008"},{"key":"bibr57-1074248414529622","unstructured":"Sarma A, Cannon CP, Wiviott SD, Higher strength statins do not increase risk of kidney injury. http:\/\/newsroom.heart.org\/news\/higher-strength-statins-do-not-increase-risk-of-kidney-injury. Updated 2013. Accessed August 13, 2013."},{"key":"bibr58-1074248414529622","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.c2197"},{"key":"bibr59-1074248414529622","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.f880"},{"key":"bibr60-1074248414529622","doi-asserted-by":"publisher","DOI":"10.1136\/jcp.2003.012989"},{"key":"bibr61-1074248414529622","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0029849"},{"key":"bibr62-1074248414529622","doi-asserted-by":"publisher","DOI":"10.4065\/mcp.2011.0123"},{"key":"bibr63-1074248414529622","doi-asserted-by":"publisher","DOI":"10.1001\/jama.288.4.455"},{"key":"bibr64-1074248414529622","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2011.12.013"},{"key":"bibr65-1074248414529622","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2013.01.033"},{"key":"bibr66-1074248414529622","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2012.04.045"},{"key":"bibr67-1074248414529622","volume-title":"Is the NHS becoming more patient-centred? Trends from the national surveys of NHS patients in England 2002-07","author":"Richards N","year":"2007"},{"key":"bibr68-1074248414529622","author":"National Collaborating Centre for Primary C","year":"2009","journal-title":"Royal College of General Practitioners (UK)"}],"container-title":["Journal of Cardiovascular Pharmacology and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1074248414529622","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1074248414529622","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1074248414529622","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T16:42:03Z","timestamp":1777394523000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1074248414529622"}},"subtitle":["The 5 Ms"],"short-title":[],"issued":{"date-parts":[[2014,4,25]]},"references-count":68,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2014,11]]}},"alternative-id":["10.1177\/1074248414529622"],"URL":"https:\/\/doi.org\/10.1177\/1074248414529622","relation":{},"ISSN":["1074-2484","1940-4034"],"issn-type":[{"value":"1074-2484","type":"print"},{"value":"1940-4034","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,4,25]]}}}